Bioniche Life Sciences (TSE:BNC) surged 50.00% up to $1.05 on news the Canadian based biopharmaceutical company has met two major milestones under its licensing agreement with Endo Pharmaceuticals: Bioniche will receive royalties totalling US$8 million for rights to their drug therapeutic treatment of non-muscle-invasive bladder cancer, Urocidin, in North America.  Furthermore, Endo Pharmaceuticals will execute its exclusive licence to develop and market the drug worldwide, and Endo will all assume the development expenses for the product. 

In July 2009, Bioniche entered into a venture deal with Endo Pharmaceuticals valued at $20 million, to develop and market the cancer drug.  The terms of the agreement projected additional payments of up to $110 million.

Headquartered in Belleville, Ontario, Bioniche Life Sciences Inc is a technology and research-based biopharmaceutical company conducting research, development and commercialization of biopharmaceuticals for human and animal health, along with projects in food safety. 

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) gained 25.26% up to $1.19 on no news; but has been garnering attention from investment researchers this week. RNN stock has gained more than 70% since Monday on heavy volume.  Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

GeoPharma, Inc. (NASDAQ:GORX) gained 11.11% up to $0.301 on no news; however the company is expected to release Q4 results today after the close of the market. . Headquartered in Largo, Florida, GeoPharma researches, develops, manufactures, and brings to market branded generic pharmaceuticals, veterinary products, health products, and functional foods.  The company is registered with both the Food and Drug Administration and the Drug Enforcement Administration.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gained 13.18% to close at $0.91 on no news with 2,251,436 shares traded. Recently the company granted Carmot Therapeutics, Inc., an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology. Carmot will use the FBLD technology, called “Chemotype Evolution,” for identifying promising drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases. Sunesis retains full rights to the technology for use in its future internal discovery efforts; however terms of the agreement were not revealed.  The company disclosed promising developments at the end of 2009: a Phase 2 Voreloxin study for leukemia proved that patients who dosed Voreloxin combined with chemotherapy had an increased survival rate. Patients with acute myeloid leukemia usually live for only about three to six months. Headquartered in South San Francisco, California, Sunesis Pharmaceuticals, Inc is a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumour cancers. Its primary product candidate is Voreloxin; an anticancer treatment is in Phase 2 development stage.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) up 18.27% to close at $2.33 after hitting an intra-day high of $2.43, on no news. The company’s lead drug candidate Seliciclib was examined by two medical journals in January and found to be successful in killing lung cancer cells through induction of cancer cell suicide; the stock jumped 152% to a 52 week high of $2.96. Headquartered in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals, Inc., is a development-stage biopharmaceutical company which discovers, develops, and commercializes novel, mechanism-targeted drugs to treat human cancers and other serious illnesses.  The company currently has 3 drug candidates in 7 clinical trial studies for the treatment of various cancers.  CYCC is trading above its 200 day moving average of $1.21 and has gained 717% from a low of $0.028 last February.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Opko Health Inc. (AMEX:OPK) jumped 21.83% up $2.12 on news the company has developed a simple blood test for Alzheimer’s disease, which assess the levels of antibodies unique to the disease with 95% accuracy. Headquartered in Miami, Florida, Opko Health, Inc., is a specialty healthcare company discovering, developing, and commercializing its proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of various disorders.

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 16.29% up to $0.919 on no news.  The stock’s intra-day high is sitting at $0.95 and trading above its 200 day moving average of $0.810. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 16.00% up to $7.25, on no news since the company reported stellar 2009 Q4 and end of year financial results last week.  Highlights of the report include an increase in net income for the last quarter of 2009 up to $15.2 million, or $0.37 per basic share, compared to net income of $10.1 million, or $0.26 per share for the same quarter of 2008. Total revenues also grew to $74.6 million for the year ended December 31, 2009, up from $56.6 million for the year ended December 31, 2008.  Based in Birmingham, Alabama, BioCryst Pharmaceuticals develops small-molecule drugs for treatment of immunological, viral, and cardiovascular diseases and disorders.  The company’s lead flu drug Peravimir has already begun selling Japan under the name Rapiacta. The US government has approved BioCryst’s Peramivir for the emergency treatment for swine flu. The company expects to continue testing Peramivir until 2011 to win full FDA approval in the U.S. BCRX has gained 494% from a 52 week trading low $1.16 in March.

A.P. Pharma, Inc. (NASDAQ:APPA) gained 15.12% up to $1.90 on no news. In January the company received a milestone royalty payment of $2.5 million for rights to Retin-A Micro and Carac it sold to an affiliate of Paul Capital Healthcare. Based in Redwood City, California, A.P. Pharma, Inc., is a pharmaceutical company developing pharmaceutical products applying its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The New Drug Application (NDA) for APF530 was submitted to the FDA in May 2009 and accepted for review in July 2009, at which time the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18, 2010.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Athersys, Inc. (NASDAQ:ATHX) jumped 27.78% up to $3.68 on heavy volume with 5,479,849 shares trading on news the company was issued two US patents protecting the intellectual rights to its non-embryonic multipotent stem cells, the applications of isolation and expansion, and related pharmaceutical compositions;  non-embryonic pluripotent stem cells, their isolation, expansion, and usage, respectively.  The new patents expand on Athersys’ existing portfolio of 14 patents with an additional120 global patent applications supporting its stem cell technology and MultiStem product platform.  Based in Cleveland, Ohio, Athersys, Inc is a biopharmaceutical company producing non-embryonic cell product candidates for the treatment of multiple diseases. Athersys also develops orally administered pharmaceuticals to treat central nervous system disorders, such as narcolepsy, excessive daytime sleepiness, and chronic fatigue associated with Parkinson’s disease and schizophrenia.  In late December the biotech company entered into an alliance with big Pharma, Pfizer, to develop Athersys’ stem cell technology, the announcement sent the stock soaring more than 400%.  The global stem cell market is currently valued at $4.5 billion and growing rapidly at a compound annual rate of 27.3%; the market is expected to be worth $15 billion by 2015.  Another driver for activity in the biopharmaceutical sector has been a recent upsurge in strategic mergers & acquisitions: a 2009 Ernst & Young report revealed merger & acquisition activity was worth $28.5 billion in deals in 2008 in the US alone. The report also explained that the biotech industry has been helped by President Barack Obama’s pronouncement that the US government should spend more than 3% of its GDP on scientific research and development. ATHX has broken through resistance and is trading above its 90 day moving average of $1.98.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

ConjuChem Biotechnologies Inc. (TSE:CJB) gained 15.00% up to $0.115 on no news since the end of January when the company announced its fiscal 2009 year end results. Based in Montreal, Quebec, ConjuChem Biotechnologies is biotechnology firm dedicated to the discovery of therapeutics focused on curing diabetes, cancer and HIV. The biotech firm currently has three drug candidates in development and the company’s diabetes treatment PC-DAC Exendin-4 recently achieved promising glycemic control and weight loss in Phase II clinical trials for Type 2 diabetes.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rose 6.37% up to $1.67 on news the company reported financial results for the quarter and 12 month period ended December 31, 2009.  The biotech company posted profits of $3 million, or +3 cents per share, up from a loss of $69.6 million, or - 72 cents per share in 2008, a loss due chiefly to cost absorbed as part of $72 million purchase of the biotechnology company Pharmacopeia.  Revenue grew 13% to $14 million compared to $12.4 million for the same period in 2008.  Ligand also provided guidance for 2010 and updates on key programs. Based in San Diego, California, Ligand discovers and develops new drugs for unmet medical needs including hepatitis, muscle wasting, frailty, inflammation, anaemia, asthma, rheumatoid arthritis and osteoporosis. Ligand has strategic partnerships with big pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Celgene, and Cephalon etc.

Naturewell, Inc. (OTC:NAWL) jumped 50.00% up to $0.0003 on no news. Based in San Diego, California, Naturewell researches and develops proprietary healthcare products for various conditions, including its migraine medication, Migraspray. NAWL has gained 200% since October 2009.

Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) advanced 23.81% up to $3.90 on no news. Based in Seattle, Washington, Trubion is a biopharmaceutical company creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Compugen Ltd.  (NASDAQ:CGEN) rose 7.07% up to $ 4.39 on news the company posted narrower losses than expected in their 2009 Q4 results. During the last quarter of 2009 the company benefitted from a partnership with Pfizer to develop their pipeline, and successfully raised capital to further fund discoveries in 2010.  The company made progress and received promising results from studies of in vivo trails for various treatment candidates for cancer and inflammation.  Based in Tel Aviv, Israel, Compugen is a drug company which discovers and commercializes its candidates by early-stage licensing and co-development deals. The company’s business is focused on developing and using predictive computer-based discovery platforms to determine therapeutic drug candidates and diagnostic biomarker candidates. GCEN stock has gained 698% since last February.

Oncolytics Biotech, Inc. (TSE:ONC) jumped 14.95% up to $3.23 on no news; however the company is expected to begin enrolment for its upcoming Phase 3 trial for Reolysin.  Reolysin is being developed as a therapeutic for the treatment of head and neck cancers.  Headquartered in Calgary, Alberta, Oncolytics Biotech, Inc is a biopharmaceutical company which discovers and develops therapeutic products for the treatment of cancer.  The company currently has more than a dozen trials at various stages in the US, UK and Canada for their lead drug candidate Reolysin. The company has a market cap of about $183 million and the financial wherewithal to fund the company through Phase 3 FDA evaluations.  According to Research and Markets the global head and neck cancer market is expected to grow at a rate of 8.3% annually for the next six years to reach $1,809M by 2016.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

RCM Technologies, Inc. (NASDAQ:RCMT) gained 12.00% to close at $2.80 and picked up from a low today of $2.86, on news the company’s Board of Directors have implemented a stock repurchase program for up to $7.5 million of RCTM’s outstanding common shares over the next 12 months. The stock repurchase program will be funded using the company’s working capital. Headquartered in Pennsauken, New Jersey, RCM Technologies, Inc. is an international technology company providing engineering services and IT division consulting.  RCTM’s stock is bullish and trading well above its 90 day moving average of $2.49 and has gained 210% from a 52 week trading low in March when the stock was moving at around $0.91.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) up 16.16% to close at $2.30 on no news; however the company will be participating at the upcoming 12th Annual BIO CEO & Investor Conference on Monday the 8^th of February, and will provide an overview of key developments. In January the company’s lead drug candidate Seliciclib was reviewed by two medical journals and found be effective in killing lung cancer cells through induction of cancer cell suicide; which sent the stock surging 152%. Headquartered in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals, Inc., is a development-stage biopharmaceutical company which discovers, develops, and commercializes novel, mechanism-targeted drugs to treat human cancers and other serious illnesses.  The company currently has 3 drug candidates in 7 clinical trial studies for the treatment of various cancers. 

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

A.P. Pharma, Inc. (NASDAQ:APPA) gained 16.42% up to $1.56 on no news since the company reported regaining  compliance with the Nasdaq minimum bid rule in January.  The company also reported receiving a royalty payment of $2.5 million for rights to Retin-A Micro and Carac it sold to an affiliate of the Paul Capital Healthcare. Based in Redwood City, California, A.P. Pharma, Inc., is a pharmaceutical company developing pharmaceutical products applying its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The New Drug Application (NDA) for APF530 was submitted to the FDA in May 2009 and accepted for review in July 2009, at which time the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18, 2010.

Zagg Inc(NDA) (NASDAQ:ZAGG) rose 17.63% up to $2.87 on news the company has already begun accepting pre-orders for invisibleSHIELD for the Apple iPad. Headquartered in Salt Lake City, Utah, ZAGG Incorporated designs, manufactures, and distributes protective coverings, audio accessories, and power solutions for consumer electronic and hand-held devices, under the invisibleSHIELD and ZAGGaudio brand names, primarily in the US and Europe.  The company’s proprietary protective coverings are outfitted for iPhones, Blackberrys, iPods, and many other electronic devices.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter